Evidence supporting the use of: L-carnitine
For the health condition: Congestive Heart Failure

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

L-carnitine is used as a supplemental therapy in the management of congestive heart failure (CHF) based on some scientific evidence, though the overall quality and strength of this evidence is moderate to low. L-carnitine is a naturally occurring amino acid derivative that plays a key role in mitochondrial fatty acid transport and energy production, which are critical processes for cardiac muscle function. Several small clinical trials and observational studies have suggested that L-carnitine supplementation may improve left ventricular function, exercise tolerance, and symptoms in patients with CHF, potentially by enhancing myocardial energy metabolism and reducing oxidative stress.

A 2013 meta-analysis of randomized controlled trials (Zhang et al., Clinical Cardiology) found that L-carnitine supplementation improved left ventricular ejection fraction and reduced all-cause mortality in CHF patients. However, the included trials were small, often single-center, and of variable methodological quality. Some studies, particularly from Italy and China, have reported benefits, but results are not uniformly positive, and large, high-quality multicenter trials are lacking. Major heart failure guidelines do not currently recommend L-carnitine as standard therapy, citing insufficient robust evidence.

In summary, while there is some scientific basis for the use of L-carnitine in CHF, the supporting evidence is limited and not definitive. Its use may be considered as adjunctive therapy in selected patients, but it should not replace proven conventional treatments.

More about l-carnitine
More about Congestive Heart Failure